DEVACELL, INC. Email Format

Biotechnology ResearchCalifornia, United States2-10 Employees

DevaCell, Inc. is a biotechnology research company based in San Diego, California. It is advancing a pipeline of therapeutic candidates built on a proprietary synthetic vector platform. The main focus areas include oncolytic cancer immunotherapy, gene therapy and gene editing, and vaccines, with a lead program using an engineered adenovirus backbone to deliver multiple transgene payloads to solid tumors and moving toward IND-enabling studies.

In infectious disease, the company is pursuing a COVID-19 vaccine based on the same backbone to express the SARS-CoV-2 spike protein, also progressing toward IND-enabling studies. Additionally, its gene therapy/gene editing program remains in discovery with plans to reach IND-enabling studies in the second half of 2021, and the firm has publicly announced a January 2021 virtual conference presentation.

Sign up for free to view info

Company overview Employee directory